Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
Portfolio Pulse from
Cellectis has drawn down the final €5 million tranche from its €40 million credit facility with the European Investment Bank. The funds will support the development of its CAR T-cell therapies.
December 10, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectis has secured the final €5 million from its €40 million credit facility with the EIB, which will be used to advance its CAR T-cell therapies, UCART22 and UCART20x22.
The completion of the credit facility provides Cellectis with necessary funds to continue developing its CAR T-cell therapies, which is a positive development for the company's growth and innovation prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100